Client is actively planning Phase III clinical trial design and seeking to gauge upside potential of incorporating multiple clinical endpoints in the studies
Client is seeking to maximize the commercial viability and return of their clinical trial investment under defined budgetary constraints
Quantitatively gauge prescribing dynamics related to the Chronic Gout Therapy market related to physician satisfaction with current treatment options and willingness to adopt new therapies
Conduct a choice-based, conjoint survey to evaluate physician preference for and sensitivity to various bundles of “attributes” for a Gout Therapy – indication, efficacy (disease treatment), safety, access, administration
Client received a “market share” simulator that allowed them to model potential product indication scenarios that would result from different product attribute claims
Client received a report detailing market sensitivity to specific product attributes and product attribute levels (i.e. one level of efficacy compared to another) allowing them to project “Best and Worst Case Scenarios” for their product’s market share expectations
